11/21
07:30 am
krro
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
Medium
Report
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
11/14
08:00 am
krro
Korro to Present at the Jefferies London Healthcare Conference
Medium
Report
Korro to Present at the Jefferies London Healthcare Conference
11/13
12:53 pm
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
Medium
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.
11/13
08:36 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at William Blair.
High
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at William Blair.
11/12
04:05 pm
krro
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
High
Report
Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/4
07:25 am
krro
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
Medium
Report
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
10/21
10:04 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at Royal Bank of Canada from $95.00 to $105.00. They now have an "outperform" rating on the stock.
Medium
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at Royal Bank of Canada from $95.00 to $105.00. They now have an "outperform" rating on the stock.
10/21
08:31 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $153.00 price target on the stock.
Medium
Report
Korro Bio, Inc. (NASDAQ: KRRO) is now covered by analysts at Raymond James. They set a "strong-buy" rating and a $153.00 price target on the stock.
10/18
08:33 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at HC Wainwright from $100.00 to $115.00. They now have a "buy" rating on the stock.
Low
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its price target raised by analysts at HC Wainwright from $100.00 to $115.00. They now have a "buy" rating on the stock.
9/30
08:00 am
krro
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
Medium
Report
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
9/19
10:55 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $95.00 price target on the stock.
Low
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $95.00 price target on the stock.
9/17
08:02 am
krro
Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
High
Report
Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.
9/16
08:00 am
krro
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
Low
Report
Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates
9/10
08:00 am
krro
Korro to Participate in Upcoming Investor Conferences
Medium
Report
Korro to Participate in Upcoming Investor Conferences
8/28
08:00 am
krro
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
Low
Report
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
8/27
08:00 am
krro
Korro to Participate in Upcoming September Investor and Scientific Conferences
Low
Report
Korro to Participate in Upcoming September Investor and Scientific Conferences